سـاب 🚺 SABB

# SAUDI BRITISH BANK

## BASEL III - CAPITAL STRUCTURE DISCLOSURE

AS AT 30th September 2014



## **Table of Contents**

Statement of Financial Position - Step 1 (Table 2(b))	Page 3
Statement of Financial Position - Step 2 (Table 2(c))	4
Common template (transition) - Step 3 (Table 2(d)) I	5
Common template (transition) - Step 3 (Table 2(d)) ii	6
Main features template of regulatory capital instruments - (Table 2(e))	7
Main features template of regulatory capital instruments - (Table 2(e) (2))	8



SAR'000

## **TABLE 2: CAPITAL STRUCTURE**

Balance sheet - Step 1 (Table 2(b))

	Balance sheet in Published financial statements (C)	Adjustment of banking associates / other entities (*) ( D )	Under regulatory scope of consolidation ( E )
Assets			
Cash and balances at central banks	15,748,557		15,748,557
Due from banks and other financial institutions	4,627,368		4,627,368
Investments, net	26,139,022		26,139,022
Loans and advances, net	116,667,761		116,667,761
Debt securities	13,489,618		13,489,618
Trading assets	0		0
Equity shares	1,300,359		1,300,359
Investment in associates	746,087		746,087
Derivatives	975,837		975,837
Goodwill	0		0
Other intangible assets	0		0
Property and equipment, net	640,143		640,143
Other assets	2,623,100		2,623,100
Total assets	182,957,852	0	182,957,852
Liabilities Due to Banks and other financial institutions	2,768,293		2,768,293
Items in the course of collection due to other banks	0		0
Customer deposits	143,687,301		143,687,301
Trading liabilities	0		0
Debt securities in issue	5,267,001		5,267,001
Derivatives	832,538		832,538
Retirement benefit liabilities	348,687		348,687
Taxation liabilities	0		0
Accruals and deferred income	571,866		571,866
Borrowings	93,750		93,750
Other liabilities	3,988,742		3,988,742
Subtotal	157,558,178	0	157,558,178
Paid up share capital	10,000,000		10,000,000
Statutory reserves	7,934,504		7,934,504
Other reserves	359,422		359,422
Retained earnings	7,105,748		7,105,748
Minority Interest	0		0
Proposed dividends	0		0
Total liabilities and equity	182,957,852	0	182,957,852

\* For further details on column D please refer to step 1 on page 16 of the guidance notes .

#### Additional information:

List of entities (including disclosure of such entities balance sheet, balance sheet activity and principal activities)



As at 30 September 2014 SAR'000

### TABLE 2: CAPITAL STRUCTURE

Balance sheet - Step 2 (Table 2(c))

	Balance sheet in Published financial statements ( C )	Adjustment of banking associates / other entities ( D )	Under regulatory scope of consolidation (E)	Reference
<u>Assets</u>				
Cash and balances at central banks	15,748,557		15,748,557	
Due from banks and other financial institutions	4,627,368		4,627,368	
Investments, net	26,139,022		26,139,022	
Loans and advances, net	116,667,761		116,667,761	
of which Collective provisions	1,175,337		1,175,337	Α
Debt securities	13,489,618		13,489,618	
Trading assets	0		0	
Equity shares	1,300,359		1,300,359	
Investment in associates	746,087		746,087	
Derivatives Goodwill	975,837 0		975,837	
Other intangible assets	0		0	
Property and equipment, net	640,143		640,143	
Other assets	2,623,100		2,623,100	
	2,020,100		2,020,100	
Total assets	182,957,852	0	182,957,852	
Liabilities	0.700.000		0.700.000	
Due to Banks and other financial institutions	2,768,293		2,768,293	
Items in the course of collection due to other banks	0		0	
Customer deposits	143,687,301		143,687,301	
Trading liabilities	0		0	
Debt securities in issue	5,267,001		5,267,001	_
of which Tier 2 capital instruments	3,000,000		3,000,000	В
Derivatives	832,538		832,538	
Retirement benefit liabilities	348,687		348,687	
Taxation liabilities	0 571,866		0 571,866	
Accruals and deferred income Borrowings	93,750		93,750	
Other liabilities	3,988,742		3,988,742	
Subtotal	157,558,178	0	, ,	
Cublotai	137,556,176	0	137,536,176	
Paid up share capital	10,000,000		10,000,000	
of which amount eligible for CET1	10,000,000		10,000,000	С
of which amount eligible for AT1	10,000,000		10,000,000	-
Statutory reserves	7,934,504		7,934,504	D
Other reserves	359,422		359,422	Ē
Retained earnings	7,105,748		7,105,748	F
SAMA Supervisory Provision Adjustment	28,331		28,331	G
Minority Interest	0		0	-
Proposed dividends	0		0	
Total liabilities and equity	182,957,852	0	182,957,852	
	,		,	I

<u>Note:</u> Items A & B have been mapped as an example to Table 2d, for further details please refer to step 2 on page 17 of the guidance notes .

As at 30 September 2014 SAR'000

#### TABLE 2: CAPITAL STRUCTURE

Common template (transition) - Step 3 (Table 2(d)) i

(From January 2013 to 2018 identical to post 2018) With amount subject to Pre- Basel III Treatment

Amounts' Source based on reference subject to numbers / letters of the Pre - Basel balance sheet under the III regulatory scope of treatment consolidation from step 2

> C F - G D + E

		reported by the bank	treatment	CO
(2)				
	Common Equity Tier 1 capital: Instruments and reserves			
1	Directly issued qualifying common share capital (and equivalent for non-joint stock companies) plus related stock surplus	10,000,000		
	Retained earnings	7,077,417		
3	Accumulated other comprehensive income (and other reserves)	8,293,926		
4	Directly issued capital subject to phase out from CET1 (only applicable to non-joint stock companies)			
	Common share capital isued by subsidiaries and held by third parties (amount allowed in group CET1)			1
	Common Equity Tier 1 capital before regulatory adjustments	25,371,343		•
	Common Equity Tier 1 capital: Regulatory adjustments			
7	Prudential valuation adjustments			i –
	Goodwill (net of related tax liability)		+	1
	Coordina (net or loaded tax income) Other intangibles other than mortgage-servicing rights (net of related tax liability)		<u></u> -	ł
	Deferred tax assets that rely on future profitability excluding those arising from temporary differences (net of related tax liability) Deferred tax assets that rely on future profitability excluding those arising from temporary differences (net of related tax liability)			1
	Casi-inow neuge reserve Shortfall of provisions to expected losses			i i
	Silutian of provisions to expected losses Securitiaation gain on sale (as set out in paragraph 562 of Basel II framework)		+	1
	Gains and losses due to changes in own credit risk on fair valued liabilities			4
	Defined-benefit pension fund net assets		L	
	Investments in own shares (if not already netted off paid-in capital on reported balance sheet)		L	I.
	Reciprocal cross-holdings in common equity			i -
18	Investments in the capital of banking, financial and insurance entities that are outside the scope of regulatory consolidation, net of eligible short			1
	positions, where the bank does not own more than 10% of the issued share capital (amount above 10% threshold)		<b></b>	ļ
19	Significant investments in the common stock of banking, financial and insurance entities that are outside the scope of regulatory consolidation, net of		í — - — - — -	1
	eligible short positions (amount above 10% threshold)			1
20	Mortgage servicing rights (amount above 10% threshold)		1	1
	Deferred tax assets arising from temporary differences (amount above 10% threshold, net of related tax liability)			i i
	Amount exceeding the 15% threshold		¦	1
23	of which: significant investments in the common stock of financials		+	
23	of which, significant investments in the common stock of mandals			1
24	or which, inorgage servicing rights of which, deferred tax assets arising from temporary differences			1
26	National specific regulatory adjustments			
ļ	REGULATORY ADJUSTMENTS APPLIED TO COMMON EQUITY TIER 1 IN RESPECT OF AMOUNTS SUBJECT TO PRE-BASEL III TREATMENT			
ļ	OF WHICH: [INSERT NAME OF ADJUSTMENT]			
<u> </u>	OF WHICH:			
	Regulatory adjustments applied to Common Equity Tier 1 due to insufficient Additional Tier 1 and Tier 2 to cover deductions			
28	Total regulatory adjustments to Common equity Tier 1			
29	Common Equity Tier 1 capital (CET1)	25,371,343		
	Additional Tier 1 capital: instruments			
30	Directly issued gualifying Additional Tier 1 instruments plus related stock surplus			
31				
32	of which: classified as liabilities under applicable accounting standards			
	Directly issued capital instruments subject to phase out from Additional Tier 1			
24	Additional Tier 1 instruments (and CET1 instruments not concluded in row 5) issued by subsidiaries and held by third parties (amount allowed in group			
34	Additional fer Finistraments (and OE FFinistraments not included in tow 5) issued by subsidiaries and field by and parties (and off a novel in group AT1			
	of which: instruments issued by subsidiaries subject to phase out			
36	Additional Tier 1 capital before regulatory adjustments			
L	Additional Tier 1 capital: regulatory adjustments	ļ		a
	Investments in own Additional Tier 1 instruments		L	1
	Reciprocal cross-holdings in Additional Tier 1 instruments		L	l.
39	Investments in the capital of banking, financial and insurance entities that are outside the scope of regulatory consolidation, net of eligible short			i.
1	positions, where the bank does not own more than 10% of the issued common share capital of the entity (amount above 10% threshold)			1
40	Significant investments in the capital of banking, financial and insurance entities that are outside the scope of regulatory consolidation (net of eligible	1	r	1
1.3			(375,882)	1
44	anon positiona) National specific regulatory adjustments		L_ <u>[373,002]</u>	
41				
}	REGULATORY ADJUSTMENTS APPLIED TO ADDITIONAL TIER 1 IN RESPECT OF AMOUNTS SUBJECT TO PRE-BASEL III TREATMENT			
	OF WHICH: [INSERT NAME OF ADJUSTMENT]			
	OF WHICH:			
	Regulatory adjustments applied to Additional Tier 1 due to insufficient Tier 2 to cover deductions			
	Total regulatory adjustments to Additional Tier 1 capital			
	Additional Tier 1 capital (AT1)			
45	Tier 1 capital (T1 = CET1 + AT1)	25,371,343		

<sup>1</sup>For detailed explanation of rows (1-85). please refer to SAMA circular # BCS 23295 dated 23 Julv 2012 entitled "Composition of Capital Disclosure Requirements issued by the BCBS in June <sup>(2)</sup> All rows related to IRB Approach are only valid. if SAMA has provided its Regulatory Approval to use IRB Approaches

Note: Items which are not applicable are to be left blank.

PUBLIC

Components<sup>1</sup> of regulatory capital reported by the bank 54

65

66

As at 30 September 2014 SAR'000

#### TABLE 2: CAPITAL STRUCTURE

Common template (transition) - Step 3 (Table 2(d)) ii

(From January 2013 to 2018 identical to post 2018) With amount subject to Pre- Basel III Treatment

Components<sup>1</sup> of regulatory capital ш regulatory scope of reported by the bank treatment consolidation from step 2 Tier 2 capital: instruments and provisions 46 Directly issued qualifying Tier 2 instruments plus related stock surplus 1,500,000 в в 47 Directly issued capital instruments subject to phase out from Tier 2 480.000 48 Tier 2 instruments (and CET1 and AT1 instruments not included in rows 5 or 34) issued by subsidiaries and held by third parties (amount allowed in group Tier 2) 49 of which: instruments issued by subsidiaries subject to phase out 1,175,337 Δ 50 Provisions 51 Tier 2 capital before regulatory adjustments 3,155,337 Tier 2 capital: regulatory adjustments 52 Investments in own Tier 2 instruments \_ \_ \_ \_ \_ \_ ٦. 53 Reciprocal cross-holdings in Tier 2 instruments Investments in the capital of banking, financial and insurance entities that are outside the scope of regulatory consolidation, net of eligible short positions, where the bank does not own more than 10% of the issued common share capital of the entity (amount above the 10% threshold) 55 Significant investments in the capital banking, financial and insurance entities that are outside the scope of regulatory consolidation (net of eligible (375,882) short positions) 56 National specific regulatory adjustments REGULATORY ADJUSTMENTS APPLIED TO TIER 2 IN RESPECT OF AMOUNTS SUBJECT TO PRE-BASEL III TREATMENT OF WHICH: [INSERT NAME OF ADJUSTMENT] OF WHICH: ... 57 Total regulatory adjustments to Tier 2 capital 3,155,337 58 Tier 2 capital (T2) 59 Total capital (TC = T1 + T2) RISK WEIGHTED ASSETS IN REPECT OF AMOUNTS SUBJECT TO PRE-BASEL III TREATMENT 28,526,680 OF WHICH: [INSERT NAME OF ADJUSTMENT] OF WHICH: .. 165,900,857 60 Total risk weighted assets Capital ratios 61 Common Equity Tier 1 (as a percentage of risk weighted assets) 15.29% 62 Tier 1 (as a percentage of risk weighted assets) 15.29% 63 Total capital (as a percentage of risk weighted assets) 17.20% 64 Institution specific buffer requirement (minimum CET1 requirement plus capital conservation buffer plus countercyclical buffer requirements plus G-SIB buffer requirement expressed as a percentage of risk weighted assets) of which: capital conservation buffer requirement of which: bank specific countercyclical buffer requirement of which: G-SIB buffer requirement 68 Common Equity Tier 1 available to meet buffers (as a percentage of risk weighted assets)
National minima (if different from Basel 3) National Common Equity Tier 1 minimum ratio (if different from Basel 3 minimum) 69 n/a 70 National Tier 1 minimum ratio (if different from Basel 3 minimum) n/a 71 National total capital minimum ratio (if different from Basel 3 minimum) n/a Amounts below the thresholds for deduction (before risk weighting) 72 Non-significant investments in the capital of other financials 73 Significant investments in the common stock of financials 74 Mortgage servicing rights (net of related tax liability) 75 Deferred tax assets arising from temporary differences (net of related tax liability) Applicable caps on the inclusion of provisions in Tier 2 1,175,337 76 Provisions eligible for inclusion in Tier 2 in respect of exposures subject to standardised approach (prior to application of cap) 77 Cap on inclusion of provisions in Tier 2 under standardised approach 1,903,444 78 Provisions eligible for inclusion in Tier 2 in respect of exposures subject to internal ratings-based approach (prior to application of cap) 79 Cap for inclusion of provisions in Tier 2 under internal ratings-based approach Capital instruments subject to phase-out arrangements (only applicable between 1 Jan 2018 and 1 Jan 2022) 80 Current cap on CET1 instruments subject to phase out arrangements 81 Amount excluded from CET1 due to cap (excess over cap after redemptions and maturities) Current cap on AT1 instruments subject to phase out arrangements 82 ( 83 Amount excluded from AT1 due to cap (excess over cap after redemptions and maturities) 84 Current cap on T2 instruments subject to phase out arrangements 85 Amount excluded from T2 due to cap (excess over cap after redemptions and maturities)

<sup>1</sup>For detailed explanation of rows (1-85), please refer to SAMA circular # BCS 23295 dated 23 July 2012 entitled "Composition of Capital Disclosure Requirements issued by the BCBS in June 2012. <sup>(2)</sup> All rows related to IRB Approach are only valid. if SAMA has provided its Regulatory Approval to use IRB Approaches

Note: Items which are not applicable are to be left blank.

Amounts<sup>1</sup> Source based on reference subject to numbers / letters of the Pre - Basel balance sheet under the



As at 30 September 2014

Main features template of regulatory capital instruments - (Table 2(e))	
1 Issuer	Saudi British Bank (SABB)
2 Unique identifier (eg CUSPIN, ISIN or Bloomberg identifier for private placement)	ISIN No. SA131VK0GJ37
	The instrument is governed by th
3 Governing law(s) of the instrument	of the Kingdom of Saudi Arabia
Regulatory treatment	
4 Transitional Basel III rules	Tier 2
5 Post-transitional Basel III rules	Ineligible
6 Eligible at solo/Igroup/group&solo	Solo
7 Instrument type	Subordinated Sukuk
8 Amount recognied in regulatory capital (Currency in mil, as of most recent reporting date)	SAR 480mil
9 Par value of instrument	SAR 1,500mil
10 Accounting classification	Liability - amortised cost
11 Original date of issuance	28th March 2012
12 Perpetual or dated	Dated
13 Original maturity date	28th March 2017
14 Issuer call subject to prior supervisory approval	Yes
	Call option only available for a
	regulatory or tax event. SABB wi
	entitled to redeem in whole, but r
	part, by giving not less than thirty
	days' not more than (60) days' no
15 Option call date, contingent call dates and redemption amount	the sukukholders.
16 Subsequent call dates if applicable	As above
Coupons / dividends	A3 200Ve
17 Fixed or Floating dividend/coupon	Floating
18 Coupon rate and any related index	3 month SIBOR + 120bps
19 Existence of a dividend stopper	No
20 Fully discretionary, partially discretionary or mandatory	Mandatory
20 Fully discretionary, partially discretionary or mandatory 21 Existence of step up or other incentive to redeem	No
	Non cumulative
23 Convertible or non-convertible	Non - convertible
24 If convertible, conversion trigger (s)	N/A
25 If convertible, fully or partially	N/A
26 If convertible, conversion rate	N/A
27 If convertible, mandatory or optional conversion	N/A
28 If convertible, specify instrument type convertible into	N/A
29 If convertible, specify issuer of instrument it converts into	N/A
30 Write-down feature	No
31 If write-down, write-down trigger (s)	N/A
32 If write-down, full or partial	N/A
33 If write-down, permanent or temporary	N/A
34 If temporary writedown, description of the write-up mechansim	N/A
	Subordinated. Senior bondholde
35 Position in subordination hierarchy in liquidation (specify instrument type immediately senior to instrument)	immediately senior to this instrum
36 Non-compliant transitioned features	Yes
37 If yes, specify non-compliant features	No writedown or non convertible

Note: Further explanation of rows (1-37) as given above are provided in SAMA circular # BCS 23295 dated 23 July 2012 entitled "Composition of Capital Disclosure Requirements issued by the BCBS in June 2012.



As at 30 September 2014

Main features template of regulatory capital instruments - (Table 2(e))	
1 Issuer	Saudi British Bank (SABB)
2 Unique identifier (eg CUSPIN, ISIN or Bloomberg identifier for private placement)	ISIN No.SA13EFK0GJJ0
	The instrument is governed by the
3 Governing law(s) of the instrument	of the Kingdom of Saudi Arabia
Regulatory treatment	
4 Transitional Basel III rules	Tier 2
5 Post-transitional Basel III rules	Eligible
6 Eligible at solo/lgroup/group&solo	Solo
7 Instrument type	Subordinated Sukuk
8 Amount recognied in regulatory capital (Currency in mil, as of most recent reporting date)	SAR 1,500mil
9 Par value of instrument	SAR 1,500mil
10 Accounting classification	Liability - amortised cost
11 Original date of issuance	17th December 2013
12 Perpetual or dated	Dated
13 Original maturity date	17th December 2020
14 Issuer call subject to prior supervisory approval	Yes
	Call option only available after 5 ye
	or for a regulatory or tax event, 17
	December 2018 as the date for
	redemption, SABB shall be entitle
	redeem in whole, but not in part, b
	giving not less than thirty (30) days
	more than sixty (60) days' notice to
15 Option call date, contingent call dates and redemption amount	Sukukholders
16 Subsequent call dates if applicable	As above
Coupons / dividends	
17 Fixed or Floating dividend/coupon	Floating
18 Coupon rate and any related index	6 months SIBOR + 140bps
19 Existence of a dividend stopper	No
20 Fully discretionary, partially discretionary or mandatory	Mandatory
21 Existence of step up or other incentive to redeem	No
22 Non cumulative or cumulative	Non cumulative
23 Convertible or non-convertible	Non - convertible
24 If convertible, conversion trigger (s)	N/A
25 If convertible, fully or partially	N/A
26 If convertible, conversion rate	N/A
27 If convertible, mandatory or optional conversion	N/A
28 If convertible, specify instrument type convertible into	N/A
29 If convertible, specify issuer of instrument it converts into	N/A
30 Write-down feature	Yes
	Terms of contract of the instrumer
	provide the legal basis for SAMA t
	trigger write-down (a contractual
31 If write-down, write-down trigger (s)	approach)
32 If write-down, full or partial	Written down fully or partial
33 If write-down, permanent or temporary	Permanent
34 If temporary writedown, description of the write-up mechansim	
	Subordinated. Senior bondholders
35 Position in subordination hierarchy in liquidation (specify instrument type immediately senior to instrument)	immediately senior to this instrume
36 Non-compliant transitioned features	N/A
37 If yes, specify non-compliant features	N/A

Note: Further explanation of rows (1-37) as given above are provided in SAMA circular # BCS 23295 dated 23 July 2012 entitled "Composition of Capital Disclosure Requirements issued by the BCBS in June 2012.